0638 FUNCTION AND WORK PRODUCTIVITY MEASURES IN A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, 12-WEEK STUDY OF THE SAFETY AND EFFICACY OF JZP-110 FOR THE TREATMENT OF EXCESSIVE SLEEPINESS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA

Abstract Introduction: Excessive sleepiness in patients with obstructive sleep apnea (OSA) is associated with reductions in function and daily activities. JZP-110 is a selective dopamine norepinephrine reuptake inhibitor with wake-promoting effects. Effects of JZP-110 on function, work productivity, and activity impairment were evaluated in a phase 3 study in patients with OSA. Methods: Eligibility criteria included: OSA diagnosis according to International Classification of Sleep Disorders-3 criteria; past or present use of a primary OSA therapy; Epworth Sleepiness Scale score ≥10; mean sleep latency